Peer-reviewed veterinary case report
Changes in dog prostate blood markers during finasteride treatment
By Golchin-Rad, Kamran et al.·Published in Topics in companion animal medicine·2020·Department of Clinical Sciences·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride.
- Species:
- dog
Plain-English summary
A group of dogs with benign prostatic hyperplasia (BPH), a condition that can cause difficulty urinating and discomfort, were treated with a medication called finasteride for one month. The treatment led to a significant reduction in prostate size and levels of certain prostate-specific markers in the blood, indicating that finasteride was effective in managing the condition. However, one specific marker, prostatic acid phosphatase (PAP), did not show any change. Overall, monitoring these markers and using ultrasound can help vets track how well the treatment is working for dogs with BPH.
People also search for: dog prostate problems treatment · finasteride for dogs BPH · dog urination issues · prostate enlargement in dogs · canine prostate health monitoring
Abstract
The monitoring of serum prostatic biomarkers during the treatment will help clinicians to know the statement of the response to finasteride in dogs affected by benign prostatic hyperplasia (BPH). The present study was aimed to assess changes in the serum canine prostate-specific esterase (CPSE), prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), testosterone, dihydrotestosterone (DHT) and prostate volume evaluation using ultrasonographic examination during the treatment with finasteride in BPH-induced dogs. Twenty dogs were divided into 4 groups (n = 5): BPH + finasteride group, dogs which were induced for BPH and received oral finasteride once daily for 1 month; BPH group, dogs which were induced for BPH and received placebo; finasteride group, normal dogs which received finasteride; and normal group, normal intact dogs which did not receive treatment. Blood sampling and ultrasonography examination were performed on days 0, 14, and 28. The administration of finasteride led to a significant decrease in the concentration of the prostate-specific biomarkers (PSA, CPSE), DHT, testosterone, and the volume of the prostate in BPH + finasteride group compared with the BPH group during 1 month. Interestingly, the PAP concentration did not change in the BPH-induced dogs and in dogs treated with finasteride. It seems that the monitoring of serum PSA and CPSE levels and ultrasonographic examination of the prostate are useful methods for following up the response to finasteride treatment in dogs affected by BPH.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32115076/